Press Releases

All Releases
AngioDynamics to Present at Upcoming Investor Conferences
Nov 04, 2013
ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
AngioDynamics Achieves CE Approval for AngioVac
Oct 29, 2013

CE Mark Covers Venous Drainage Cannula and Cardiopulmonary Bypass Circuit; Cannula Indicated for Removal of Fresh, Soft Thrombi or Emboli

AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
Oct 10, 2013
Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company
AngioDynamics Signs Multi-Year, Sole-Source Agreement With Large Integrated Delivery Network Group
Oct 10, 2013
ALBANY, N.Y. , Oct. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has signed a sole-source, three-year port product agreement
AngioDynamics Announces First Patient Enrolled in PICC Related Obstruction of Flow (PROOF) Study
Oct 03, 2013

Multi-Center Study Investigates Whether BioFlo PICCs Are Associated With Reduced Catheter-Related Thrombosis

AngioDynamics Announces Debt Refinancing
Sep 24, 2013
ALBANY, N.Y. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it amended its existing credit facilities and successfully
AngioDynamics Extends Licensing Agreement With Interface Biologics to Include Central Venous Catheters (CVCs)
Sep 23, 2013
ALBANY, N.Y. , Sept. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc. (IBI), a privately-held commercial stage developer
AngioDynamics to Report Fiscal 2014 First Quarter Financial Results
Sep 19, 2013
ALBANY, N.Y. , Sept. 19, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 first quarter financial results
AngioDynamics to Launch Tip Location System in Canada
Sep 18, 2013

Celerity System to be Showcased at AVA 2013

AngioDynamics to Present at the Stifel Nicolaus 2013 Healthcare Conference
Aug 28, 2013
ALBANY, N.Y. , Aug. 28, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the Stifel Nicolaus 2013 Healthcare Conference on
AngioDynamics Announces First Patient Enrolled in Clinical Research Office of the Endourological Society (CROES) NanoKnife Safety and Efficacy Study
Aug 21, 2013

Multi-Center Study Focused on the Ablation of Prostate Cancer

AngioDynamics Earns FDA Clearance for Ports With BioFlo Technology to Reduce Catheter-Related Thrombus
Aug 20, 2013
ALBANY, N.Y. , Aug. 20, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. Food and Drug Administration has granted 510(k) clearance to
AngioDynamics Applauds National Institute for Health and Care Excellence's (NICE) Updated Guidelines for Varicose Vein Treatment
Aug 19, 2013

Decision Expands Patient Access to Minimally Invasive Treatments Like the VenaCure EVLT System in the United Kingdom

AngioDynamics to Present at 33rd Annual Canaccord Growth Conference
Aug 01, 2013
ALBANY, N.Y. , Aug. 1, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 33 rd Annual Canaccord Growth Conference on
AngioDynamics Presents the St. Jude Gala
Aug 01, 2013

Event Promises to be the Premier Gala Supporting St. Jude in the Capital Region

AngioDynamics Reports Fiscal 2013 Fourth Quarter Financial Results
Jul 11, 2013
Net sales of $90 million GAAP net loss of $0.02 per share; Adjusted (Non-GAAP) net income of $0.07 per share Adjusted EBITDA Grows 56% to $12.3 million Operating cash flow of $10.8 million versus $1 million of cash used in prior year Company Introduces Financial Guidance for FY 2014 ALBANY, N.Y.
AngioDynamics Announces FDA Clearance for Xcela Plus Port Family With PASV Technology
Jun 27, 2013

Company Also Earns Health Canada Clearance for Smart Port Power-Injectable Ports

AngioDynamics to Report Fiscal 2013 Fourth Quarter and Full Year Financial Results and Hold Conference Call on July 11, 2013
Jun 25, 2013
ALBANY, N.Y. , June 25, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2013 fourth
FDA Grants Prostate IDE Approval for AngioDynamics' NanoKnife System
Jun 18, 2013

Pending U.S. Study Parallels European Prostate Efforts

Premier Selects AngioDynamics' BioFlo PICC as a Breakthrough Technology
Jun 12, 2013

BioFlo Technology Highlighted During Fifth Annual Innovation Celebration

Displaying 121 - 140 of 621

Copyright Nasdaq. Minimum 15 minutes delayed.